ESMO 2022
ESMO 2022
European Society for Medical Oncology Congress 2022
Akhil Abraham Saji, MDJournal | October 24, 2022
Abiraterone acetate + prednisolone is compared to enzalutamide + AAP for mHSPC cancer starting androgen-deprivation therapy.
Read More
Akhil Abraham Saji, MDJournal | October 24, 2022
Results from the phase 3 PROpel trial on abiraterone + olaparib vs abiraterone + placebo as first-line therapy for MCRPC
Leah LawrenceESMO 2022 | September 16, 2022
Neoadjuvant platinum-based chemotherapy has been found effective for treating metastatic penile squamous cell carcinoma.
Leah LawrenceESMO 2022 | September 16, 2022
A new study has found an association between neurodevelopmental disorders and testicular seminoma.
Leah LawrenceESMO 2022 | September 16, 2022
CLEAR study results showed that treatment with first-line lenvatinib plus pembrolizumab had clinical benefit at 2 years.
Leah LawrenceESMO 2022 | September 16, 2022
The RACE IT trial finds neoadjuvant radio-immunotherapy followed by radical cystectomy a safe and feasible treatment option.
Patrick DalyESMO 2022 | September 14, 2022
Patients with mCRPC with AR alterations had significantly worse survival outcomes compared with patients with wild-type.
Patrick DalyESMO 2022 | September 14, 2022
A meta-analysis found that triplet regimens with darolutamide and APP improved survival in mCSPC with high volume of disease.
Patrick DalyESMO 2022 | September 14, 2022
Pembro plus AAP sustained antitumor activity with acceptable safety signals in patients with mCRPC after 2 years.
Patrick DalyESMO 2022 | September 14, 2022
PRESTO trial results show adding APA and AAP to ADT improved biochemical PFS in patients with relapsed prostate cancer.
The UromigosThe Uromigos | September 13, 2022
Peter O'Donnell describes the randomized phase 2 study on enfortumab vedotin and pembrolizumab against pembrolizumab alone.
Patrick DalyESMO 2022 | September 12, 2022
177Lu-PSMA-RLT showed efficacy and safety consistent with published evidence in cohort of very old patients with mCRPC.
Patrick DalyESMO 2022 | September 12, 2022
Karim Fizazi discussed preliminary findings on ODM-208, a first-in-class CYP11A1 inhibitor at ESMO 2022.
Patrick DalyESMO 2022 | September 12, 2022
Late-breaking data from 2 randomized phase 3 trials that followed STAMPEDE protocol were presented at the ESMO Congress 2022.
The UromigosThe Uromigos | September 12, 2022
Nizar Tannir describes this randomized phase 3 study on bempegaldesleukin plus nivolumab as presented at ESMO.
The UromigosThe Uromigos | September 11, 2022
The phase III PRESTO study examined the effects of androgen suppressants on biochemically relapsed prostate cancer. 
The UromigosThe Uromigos | September 11, 2022
Axel Bex summarizes the ipi/nivo, pembro and atezo studies that were presented at ESMO 2022. 
The UromigosThe Uromigos | September 10, 2022
Mohamad Allaf gives a recap of the open-label PROSPER study on neoadjuvant nivolumab in RCC.
Patrick DalyESMO 2022 | September 10, 2022
Researchers evaluated immune effects of enzalutamide in patients with metastatic castration-resistant prostate cancer on ADT.
Patrick DalyESMO 2022 | September 10, 2022
Pembrolizumab plus olaparib did not improve survival versus alternating from abiraterone or enzalutamide in mCRPC.
Advertisement
Advertisement